Physician profile
Eric Ferris
NPI 1013129352
$1,058.18
in general payments reported to CMS, 2019-2025
14 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.21 · 2020: $23.34 · 2021: $109 · 2022: $121 · 2023: $292 · 2024: $231 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $765.87 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $278.76 | 2024-2025 | Vevye |
| Alcon Vision LLC | $234.25 | 2021-2025 | Clareon, Argos, Wavelight Refractive Suite |
| Glaukos Corporation | $111.55 | 2021-2025 | Photrexa Viscous and Photrexa |
| Bausch & Lomb Americas INC. | $104.94 | 2023 | Infuse |
| Rxsight INC | $72.60 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Kala Pharmaceuticals, INC. | $44.73 | 2021 | |
| Biotissue Holdings INC. | $42.74 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $37.55 | 2019-2020 | |
| Abbvie INC. | $36.15 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $26.75 | 2021-2025 | |
| Oyster Point Pharma, INC. | $19.21 | 2023 | Tyrvaya |
| Coopervision INC. | $18.38 | 2025 | Clariti Contact Lens |
| Dompe US, INC. | $17.01 | 2022 | |
| Sight Sciences, INC. | $13.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ferris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.